ISLB 2022 | Developments in liquid biopsy for breast cancer over 10 years

Massimo Cristofanilli, MD, FACP, Weill Cornell Medicine, New York, NY, discusses how liquid biopsy research has advanced over the last ten years. Areas of investigation include the potential use of circulating tumour cells (CTCs) and HER2 expression as prognostic and predictive biomarkers, as well as the identification of actionable mutations for novel therapeutics. Dr Cristofanilli also talks on HER2-low disease and discusses how liquid biopsy can be used for the detection of minimal residual disease (MRD). This interview took place at the International Society of Liquid Biopsy (ISLB) 2022 congress in Miami, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.